[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658794":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":28,"studyPopulation":20,"armGroups":29,"interventions":42,"overallOfficials":20,"centralContacts":50,"locations":56,"responsibleParty":74,"collaborators":20,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":20,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":20,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":20,"overallStatus":58,"whyStopped":20,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Cairo University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":20},[9],{"measure":10,"description":11,"timeFrame":12},"Maximal Interincisal Opening (MIO)","measuring in millimeters using ruler","3 months",[14,17],{"measure":15,"description":16,"timeFrame":12},"Pain Intensity","Visual Analog Scale (0-10)",{"measure":18,"description":19,"timeFrame":12},"Return of disc to normal position","using MRI imaging",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":6,"observationalModel":20,"timePerspective":20,"maskingInfo":24},"RANDOMIZED","PARALLEL",{"masking":25,"maskingDescription":20,"whoMasked":26},"SINGLE",[27],"OUTCOMES_ASSESSOR","To compare the efficacy of retro discal injection of calcium gluconate-activated PRP versus non-activated PRP in adults with Anterior Disc Displacement With Reduction (ADDWR). Efficacy will be measured by the reduction of symptoms and the restoration of function, specifically targeting the normal Maximum Mouth Opening (MMO) range.\n\nAlthough laboratory evidence indicates that activation with Calcium Gluconate significantly enhances growth factor release compared to non-activated (resting) PRP, it remains clinically unproven whether this biochemical advantage translates into superior symptomatic relief and functional disc repositioning in TMJ patients. This trial seeks to determine if the additional step of activation yields a statistically significant clinical benefit over the simpler, non-activated technique.\n\nBy combining the biologically optimized injectate (Calcium Gluconate-Activated PRP) with the anatomically specific retrodiscal injection site-which is critical for addressing disc instability-this study aims to define a superior, evidence-based protocol. Determining the efficacy of this specific combination is essential for establishing a \"gold standard\" for non-surgical ADDWR management.",[30,36],{"label":31,"type":32,"description":33,"interventionNames":34},"activated platelet-rich plasma","EXPERIMENTAL","Intra-articular retro discal injection of autologous platelet-rich plasma (PRP)",[35],"Procedure: activated platelet-rich plasma",{"label":37,"type":38,"description":39,"interventionNames":40},"non-activated platelet-rich plasma","ACTIVE_COMPARATOR","Intra-articular retrodiscal injection of autologous non-activated platelet-rich plasma",[41],"Procedure: non-activated platelet-rich plasma",[43,47],{"type":44,"name":31,"description":45,"armGroupLabels":46,"otherNames":20},"PROCEDURE","Intra-articular retrodiscal injection of autologous platelet-rich plasma (PRP) activated with 0.5 milliliters of 10% sterile calcium gluconate per 5 milliliters of prepared PRP, administered as a single anatomical landmark-guided injection into the retrodiscal tissue.",[31],{"type":44,"name":37,"description":48,"armGroupLabels":49,"otherNames":20},"Intra-articular retrodiscal injection of autologous non-activated platelet-rich plasma, prepared using identical double-centrifugation technique and administered using identical injection protocol and volume",[37],[51],{"name":52,"role":53,"phone":54,"phoneExt":20,"email":55},"Mohamed A. Osama, BDS","CONTACT","01013127607","mohamed.madkour@dentistry.cu.edu.eg",[57],{"facility":5,"status":58,"city":59,"state":20,"zip":20,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"RECRUITING","Cairo","Egypt","EG",{"type":63,"coordinates":64},"Point",[65,66],31.24967,30.06263,{"lat":66,"lon":65},[69,70],{"name":52,"role":53,"phone":54,"phoneExt":20,"email":55},{"name":71,"role":53,"phone":72,"phoneExt":20,"email":73},"Nada Abd El Sattar Mohamed Kotb","01281679119","nada_abdelsattar@dentistry.cu.edu.eg",{"type":75,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Mohamed Ahmed Osama Madkour ElSayed","Master's degree Student","100658794","calcium-gluconate-activated-in-anterior-disc-displacement-with-reduction-of-the-temporomandibular-joint-100658794",false,"NCT07855887","Calcium Gluconate Activated in Anterior Disc Displacement With Reduction of the Temporomandibular Joint","Calcium Gluconate Activated Versus Non-Activated Platelet Rich Plasma in Anterior Disc Displacement With Reduction of the Temporomandibular Joint: Randomized Clinical Trial.","Inclusion Criteria:\n\n* Adults aged 18-65 years.\n* Clinical and MRI diagnosis of ADDWR per DCTMD criteria.\n* Baseline VAS pain score 4-10.\n* Failure of at least 2 conservative treatments (splint therapy, physiotherapy, NSAIDs) for 3 months.\n* Written informed consent.\n\nExclusion Criteria:\n\n* • Systemic inflammatory arthritis (Rheumatoid arthritis, etc.).\n\n  * Recent TMJ surgery or intra-articular injection within the last 6 months.\n  * Pregnancy or lactation.\n  * Active TMJ infection or malignancy.\n  * Coagulopathy or anticoagulant therapy.\n  * Contraindications to MRI (e.g., pacemaker).","ALL","18 Years","65 Years",{"count":89,"type":90},20,"ESTIMATED","INTERVENTIONAL",[93],"NA","To compare the efficacy of retro discal injection of calcium gluconate-activated PRP versus non-activated PRP in adults with Anterior Disc Displacement with Reduction (ADDWR). Efficacy will be measured by the reduction of symptoms and the restoration of function, specifically targeting the normal Maximum Mouth Opening (MMO) range",[96],"Temporomandibular Joint Disorders","2026-09-28",{"date":99,"type":100},"2026-10-02","ACTUAL",{"date":102,"type":100},"2026-07-25",{"date":104,"type":90},"2026-11",{"name":5,"class":6},1]